Literature DB >> 22502592

Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.

Zhaohua Zheng1, Syazwani I Amran, Jiuxiang Zhu, Oleg Schmidt-Kittler, Kenneth W Kinzler, Bert Vogelstein, Peter R Shepherd, Philip E Thompson, Ian G Jennings.   

Abstract

The binding mechanism of a new class of lipid-competitive, ATP non-competitive, p110α isoform-selective PI3K (phosphoinositide 3-kinase) inhibitors has been elucidated. Using the novel technique of isoform reciprocal mutagenesis of non-conserved amino acids in the p110α and p110β isoforms, we have identified three unique binding mechanisms for the p110α-selective inhibitors PIK-75, A-66S and J-32. Each of the inhibitor's p110α-isoform-selective binding was found to be due to interactions with different amino acids within p110. The PIK-75 interaction bound the non-conserved region 2 amino acid p110α Ser(773), A-66S bound the region 1 non-conserved amino acid p110α Gln(859), and J-32 binding had an indirect interaction with Lys(776) and Ile(771). The isoform reciprocal mutagenesis technique is shown to be an important analytical tool for the rational design of isoform-selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22502592      PMCID: PMC3474370          DOI: 10.1042/BJ20120499

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 3.  Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Authors:  Sandra B Gabelli; Krisna C Duong-Ly; Evan T Brower; L Mario Amzel
Journal:  Adv Enzyme Regul       Date:  2010-10-28

4.  Phosphoinositide-3-kinases (PI3Ks): combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110alpha.

Authors:  Raphaël Frédérick; William A Denny
Journal:  J Chem Inf Model       Date:  2008-02-15       Impact factor: 4.956

Review 5.  The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.

Authors:  Arvin C Dar; Kevan M Shokat
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

Review 6.  New phosphatidylinositol 3-kinase inhibitors for cancer.

Authors:  Daniel W Bowles; Antonio Jimeno
Journal:  Expert Opin Investig Drugs       Date:  2011-04       Impact factor: 6.206

7.  Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Authors:  Minghao Sun; Petra Hillmann; Bianca T Hofmann; Jonathan R Hart; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

8.  Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.

Authors:  Mark Frazzetto; Cenk Suphioglu; Jiuxiang Zhu; Oleg Schmidt-Kittler; Ian G Jennings; Susan L Cranmer; Shaun P Jackson; Kenneth W Kinzler; Bert Vogelstein; Philip E Thompson
Journal:  Biochem J       Date:  2008-09-15       Impact factor: 3.857

9.  PI3Kα inhibitors that inhibit metastasis.

Authors:  Oleg Schmidt-Kittler; Jiuxiang Zhu; Jian Yang; Guosheng Liu; William Hendricks; Christoph Lengauer; Sandra B Gabelli; Kenneth W Kinzler; Bert Vogelstein; David L Huso; Shibin Zhou
Journal:  Oncotarget       Date:  2010-09

10.  The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.

Authors:  Alex Berndt; Simon Miller; Olusegun Williams; Daniel D Le; Benjamin T Houseman; Joseph I Pacold; Fabrice Gorrec; Wai-Ching Hon; Yi Liu; Christian Rommel; Pascale Gaillard; Thomas Rückle; Matthias K Schwarz; Kevan M Shokat; Jeffrey P Shaw; Roger L Williams
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

View more
  7 in total

1.  Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.

Authors:  Xiaoli Bian; Wangqing Dong; Yang Zhao; Rui Sun; Wanjun Kong; Yiping Li
Journal:  J Mol Model       Date:  2014-03-16       Impact factor: 1.810

2.  L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ

Authors:  Jo-Anne Pinson; Zhaohua Zheng; Michelle S Miller; David K Chalmers; Ian G Jennings; Philip E Thompson
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

3.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Authors:  KiBem Kim; Andrew D Skora; Zhaobo Li; Qiang Liu; Ada J Tam; Richard L Blosser; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

4.  High-throughput screening campaigns against a PI3Kα isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds.

Authors:  Jia Wang; Grace Qun Gong; Yan Zhou; Woo-Jeong Lee; Christina Maree Buchanan; William Alexander Denny; Gordon William Rewcastle; Jackie Diane Kendall; James Michael Jeremy Dickson; Jack Urquhart Flanagan; Peter Robin Shepherd; De-Hua Yang; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

Review 5.  Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches.

Authors:  Siba Shanak; Najlaa Bassalat; Ahmad Barghash; Sleman Kadan; Mahmoud Ardah; Hilal Zaid
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-20       Impact factor: 2.629

6.  New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound.

Authors:  Xiuyan Yang; Xi Zhang; Min Huang; Kun Song; Xuefen Li; Meilang Huang; Linghua Meng; Jian Zhang
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

Review 7.  PI3K inhibitors: review and new strategies.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Chem Sci       Date:  2020-05-19       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.